Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Cardiogenesis initiates enrollment in PHOENIX System Feasibility Study

Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of diffuse coronary artery disease, reported the enrollment of the first two patients in its PHOENIX Feasibility Study. Dr. Guillermo Reyes at La Princesa Hospital, Madrid, Spain performed the procedures utilizing the company's proprietary PHOENIX System that combines the intramyocardial delivery of stem cells with transmyocardial revascularization (TMR).

13 Oct 2010

Woman’s socioeconomic status impacts clinicians' decisions for contraception: Study

A woman's race/ethnicity and socioeconomic status impact whether health care providers recommend one of the most highly effective forms of contraception, a UCSF study confirms. The results also indicate that the interaction of both factors plays a role in clinicians' decisions.

12 Oct 2010

Study finds no association between gene variant and risk of coronary disease

A genetic marker touted as a predictor of coronary artery disease is no such thing, according to a study led by researchers at the Stanford University School of Medicine.

7 Oct 2010

Researchers investigate whole-genome data to uncover new mutations for CAD risk

The Coronary ARtery DIsease Genome-wide Replication And Meta-Analysis (CARDIoGRAM) published in Circulation Cardiovascular Genetics, an American Heart Association journal consists of data from every published whole-genome study on genetic mutations in heart attack or CAD risk. Researchers are also pooling data from several unpublished genome-wide association studies to see if any new mutations can be uncovered.

6 Oct 2010

CardioDx publishes PREDICT trial results

CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced publication of results from the Personalized Risk Evaluation and Diagnosis In the Coronary Tree (PREDICT) trial in the Annals of Internal Medicine, the journal of the American College of Physicians.

5 Oct 2010

Increase in levels of P450 protein creates EET molecules that lower blood pressure

If you are one of the millions of Americans with high blood pressure, more help is on the way. That's because a new research study published in the October 2010 print issue of The FASEB Journal shows that a protein, called P450, metabolizes arachidonic acid in our blood vessel walls to create a tiny molecule with a big name-epoxyeicosatrienoic acid (EET)-which in mice, turns off genes responsible for vascular inflammation and ultimately relaxes blood vessels to lower blood pressure. This protein and genes are also present in humans.

1 Oct 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Study analyses CT for screening of coronary artery calcification in radiation-induced cancer cases

A study based on computer modeling of radiation risk suggests that widespread screening for the buildup of calcium in the arteries using computed tomography scans would lead to an estimated 42 additional radiation-induced cancer cases per 100,000 men and 62 cases per 100,000 women, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Sep 2010

Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure: CLUE study

Results from the CLUE study, a head-to-head comparison between Ready-to-Use Cardene I.V. (nicardipine) and labetalol in the emergency room, showed that Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure more effectively than labetalol. These data were presented today at the annual meeting of the American College of Emergency Physicians (ACEP) in Las Vegas, Nevada.

29 Sep 2010

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.

28 Sep 2010

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Clinical Data, Inc., today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD).

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

MTHFD1L gene may increase risk of developing late-onset Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common form of the disease. The gene, abbreviated as MTHFD1L, is on chromosome six, and was identified in a genome-wide association study.

24 Sep 2010

New data demonstrates safety and efficacy of Resolute drug-eluting stent

Coronary artery disease, a leading cause of death and poor quality of life worldwide, runs the gamut from simple to complex, which complicates the daily practice of interventional cardiology. New clinical data from a second, large international study that enrolled "all comers," regardless of disease complexity and comorbidities, again demonstrated the strong performance of the Resolute drug-eluting stent (DES) from Medtronic, Inc. for patients across this continuum.

24 Sep 2010

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Lutonix, Inc., headquartered in Minneapolis, MN, today announced six-month data from three separate drug coated balloon studies presented at the TransCatheter Therapeutics (TCT) meeting this week demonstrated the ability of the Moxy Drug Coated Balloon Catheter to inhibit restenosis in both peripheral and coronary arteries.

24 Sep 2010

Use of CYPHER stent in diabetic patients can result in significant cost savings

New analysis presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010) in Washington, DC, indicates that the broad use of CYPHER Sirolimus-eluting coronary stent in patients with diabetes would result in substantial cost savings, as compared to the use of everolimus-eluting stents (EES), paclitaxel-eluting stents (PES), or zotarolimus-eluting stents (ZES).

23 Sep 2010

Abbott announces positive results of bioresorbable vascular device at TCT conference

Abbott today announced positive nine-month results from the first 45 patients enrolled in the second stage of the ABSORB trial. At nine months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results that remained consistent with the six-month data from the same 45-patient group, with the rate of major adverse cardiac events (MACE) unchanged at 4.4 percent and no reports of blood clots (thromboses).

23 Sep 2010

Study finds adverse cardiac events rare during year after negative cardiac CTA scan

Adverse cardiac events are rare one year after patients are admitted to the emergency room with low-to-moderate risk chest pain and are discharged due to a negative cardiac computed tomography angiogram (CTA), according to a study in the October issue of the American Journal of Roentgenology. Cardiac CTA is a noninvasive heart-imaging test that determines whether fatty deposits or calcium deposits have built up in the coronary arteries that supply blood to the heart muscle.

23 Sep 2010

MAQUET enrolls first patient in OPTION trial

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced enrollment of the first patient in the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial which is designed to assess patient outcomes using a standardized, best practices approach in endoscopic vessel harvesting (EVH) for coronary artery bypass graft surgery (CABG) compared with open vein harvesting methods.

23 Sep 2010

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.

23 Sep 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Cardiogenesis initiates enrollment in PHOENIX System Feasibility Study

Woman’s socioeconomic status impacts clinicians' decisions for contraception: Study

Study finds no association between gene variant and risk of coronary disease

Researchers investigate whole-genome data to uncover new mutations for CAD risk

CardioDx publishes PREDICT trial results

Increase in levels of P450 protein creates EET molecules that lower blood pressure

Cardium expands wound healing and tissue regeneration portfolio

Study analyses CT for screening of coronary artery calcification in radiation-induced cancer cases

Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure: CLUE study

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

MTHFD1L gene may increase risk of developing late-onset Alzheimer's disease

New data demonstrates safety and efficacy of Resolute drug-eluting stent

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Use of CYPHER stent in diabetic patients can result in significant cost savings

Abbott announces positive results of bioresorbable vascular device at TCT conference

Study finds adverse cardiac events rare during year after negative cardiac CTA scan

MAQUET enrolls first patient in OPTION trial

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in